Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Hochhaus, Andreas; Réa, Delphine; Boquimpani, Carla; Minami, Yosuke; E. Cortes, Jorge; P. Hughes, Timothy; F. Apperley, Jane; Lomaia, Elza; Voloshin, Sergey; Turkina, Anna; Kim, Dong-Wook; Abdo, Andre; Maria Fogliatto, Laura; le Coutre, Philipp; Sasaki, Koji; Dong Hwan Kim, Dennis; Saussele, Susanne; Annunziata, Mario; Chaudhri, Naeem; Chee, Lynette; García-Gutiérrez, Valentin; Kapoor, Shruti; Allepuz, Alex; Quenet, Sara; Bédoucha, Véronique; J. Mauro, Michael

doi:10.1038/s41375-023-01829-9

Public

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Shared by NobleBlocks on Jan 28, 2023 • 12:00 AM UTC

Authors:

Andreas Hochhaus

Delphine Réa

Carla Boquimpani

Abstract

Abstract Asciminib, the first BCR::ABL1 inhibitor that S pecifically T argets the A BL M yristoyl P ocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (CML-CP) treated with ≥2 prior tyrosine kinase inhibito...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!